Medical Research Council (MRC) @The_MRC on Twitter Update

Home Funding Research News Having trouble viewing this email? Click here to view in a browser Medical Research Council The_MRC 03 Feb RT @iamhrf: ⭐️APPLICATIONS NOW OPEN⭐️ Are you an expert in measuring #mentalhealth experiences, demographics and functioning? Apply now t… Details  |  Retweet Medical Research Council The_MRC 03 Feb RT @uk_biobank: NEW: UK Biobank COVID-19 antibody study, released today, found that 8.8% of the UK population had been infected by December… Details  |  Retweet Medical Research Council The_MRC 03 Feb RT @DrAPitman: This interview covers the findings of our @UCLPsychiatry @The_MRC study investigating the impact of #bereavement by the #sui… Details  |  Retweet Medical Research Council The_MRC 03 Feb More than 60% of the UK's strictly-Orthodox Jewish community may have had COVID-19 in 2020, according to preliminar… https://t.co/cOt98jjnuO Details  |  Retweet Medical Research Council The_MRC 03 Feb RT @MattHancock: This news about the Oxford vaccine is absolutely superb. 📉 2/3 reduction in transmission 💉 Stronger protection from 12… Details  |  Retweet Medical Research Council The_MRC 03 Feb RT @MattHancock: This is a really encouraging study - THANK YOU to the teams at @UniofOxford & @AstraZeneca. Vaccines are the way out of t… Details  |  Retweet Medical Research Council The_MRC 02 Feb RT @UniofOxford: VACCINE UPDATE: New study shows that the #OxfordVaccine offers protection of 76% up to 12 weeks after a single dose, with… Details  |  Retweet Medical Research Council The_MRC 02 Feb RT @UniofOxford: Further analysis also shows that the #OxfordVaccine may have a substantial effect on coronavirus transmission, with 67% re… Details  |  Retweet Medical Research Council The_MRC 02 Feb RT @MRC_Outbreak: IN THE NEWS: Latest publication @ScienceMagazine ➡️As of October 2020, individuals aged 20-49 were the only groups sust… Details  |  Retweet Manage preferences Unsubscribe Contact us Help You are receiving this email because you subscribed to one or more of the Medical Research Council's email alerts using this address. We use third-party service providers, such as GovDelivery, to send out email alerts on our behalf. The data you provided in subscribing to this alert (in this case your email address) will not be used for any other reason and will never be passed on to any other third party for another purpose. If you choose to enter a password to manage your subscription preferences this is held securely and is not accessible to anyone at either the MRC or GovDelivery.

 

---

STAY CONNECTED:

SUBSCRIBER SERVICES:
Manage Preferences  |  Unsubscribe  |  Contact us | Visit our blog  |  Help

You are receiving this email because you subscribed to one or more of the Medical Research Council's email alerts using this address. We use third-party service providers, such as GovDelivery, to send out email alerts on our behalf. The data you provided in subscribing to this alert (in this case your email address) will not be used for any other reason and will never be passed on to any other third party for another purpose. If you choose to enter a password to manage your subscription preferences this is held securely and is not accessible to anyone at either the MRC or GovDelivery.

 

---

This email was sent to ooseims.archieves@blogger.com using GovDelivery Communications Cloud on behalf of: Medical Research Council • 2nd Floor, David Phillips Building, Polaris House, North Star Ave, Swindon, SN2 1FL